All posts tagged: Joints

Synthetic Cannabinoids Provide Evidence for Targeting Cannabinoid Receptors in the Treatment of Autoimmune Diseases

Pharmaceutical Cannabis Derivatives Help Discover their Receptors and Functions for Autoimmune Illnesses

A recent study conducted by Michigan State University exposed the potential for cannabinoid receptor 2 (CB2) to target the treatment of inflammatory conditions. Elevated levels of plasmacytoid dendritic cells (pCD, a type of cell in the immune system) contribute to chronic inflammation in autoimmune diseases, such as Rheumatoid Arthritis. Researchers found that synthetic CB2 agonists reported comparable benefits to THC, but minimized the cerebral effects as the psychotropic activity is mediated by cannabinoid receptor 1 (CB1). This evidence demonstrates the potential benefits of CB2-targeted treatment for inflammatory conditions. Unfortunately, there are serious concerns about the misuse of some synthetic cannabinoids, so there is still a missing bridge, in products and public education, between these research products and potential therapeutic pharmaceuticals, down the road.

View this review (yellow link) or download:

This paper is also stored here:  http://bit.ly/2HZ6cWb  inside the CED Foundation Archive

To explore related information, click keywords:

Benjamin Caplan, MDSynthetic Cannabinoids Provide Evidence for Targeting Cannabinoid Receptors in the Treatment of Autoimmune Diseases
read more

Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?

Because of the associated anti-inflammatory action, modulation of CB1R & CB2R is helpful to treat autoimmune diseases, including Multiple Sclerosis, Type-1 Diabetes Mellitus, and Rheumatoid Arthritis The full list is truly very much longer, as every illness necessarily involves the immune system and cellular communication.

The following review, written by Elaine D. Gonc ̧alves

The following review, written by Daphna Katz-Talmor: (yes, same name, unfortunately!)

Benjamin Caplan, MDCannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?
read more